These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36648658)

  • 21. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists.
    Verdalles U; Goicoechea M; García de Vinuesa S; Torres E; Hernández A; Verde E; Pérez de José A; Luño J
    Nefrologia (Engl Ed); 2020; 40(1):65-73. PubMed ID: 31451203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension.
    Martin-Lorenzo M; Martinez PJ; Baldan-Martin M; Lopez JA; Minguez P; Santiago-Hernandez A; Vazquez J; Segura J; Ruiz-Hurtado G; Vivanco F; Barderas MG; Ruilope LM; Alvarez-Llamas G
    Hypertension; 2019 Apr; 73(4):794-802. PubMed ID: 30712426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea.
    Yang L; Zhang H; Cai M; Zou Y; Jiang X; Song L; Liang E; Bian J; Wu H; Hui R
    Clin Exp Hypertens; 2016; 38(5):464-8. PubMed ID: 27367159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population.
    Djoumessi RN; Noubiap JJ; Kaze FF; Essouma M; Menanga AP; Kengne AP; Mbanya JC; Sobngwi E
    BMC Res Notes; 2016 Mar; 9():187. PubMed ID: 27007793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.
    Rosa J; Widimský P; Waldauf P; Lambert L; Zelinka T; Táborský M; Branny M; Toušek P; Petrák O; Čurila K; Bednář F; Holaj R; Štrauch B; Václavík J; Nykl I; Krátká Z; Kociánová E; Jiravský O; Rappová G; Indra T; Widimský J
    Hypertension; 2016 Feb; 67(2):397-403. PubMed ID: 26693818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of aldosterone levels by -344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension.
    Fontana V; de Faria AP; Barbaro NR; Sabbatini AR; Modolo R; Lacchini R; Moreno H
    J Am Soc Hypertens; 2014 Mar; 8(3):146-51. PubMed ID: 24388430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
    Elinoff JM; Rame JE; Forfia PR; Hall MK; Sun J; Gharib AM; Abd-Elmoniem K; Graninger G; Harper B; Danner RL; Solomon MA
    Trials; 2013 Apr; 14():91. PubMed ID: 23547564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of low-dose spironolactone on resistant hypertension.
    Engbaek M; Hjerrild M; Hallas J; Jacobsen IA
    J Am Soc Hypertens; 2010; 4(6):290-4. PubMed ID: 21130975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spironolactone for hypertension.
    Batterink J; Stabler SN; Tejani AM; Fowkes CT
    Cochrane Database Syst Rev; 2010 Aug; (8):CD008169. PubMed ID: 20687095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study.
    Parthasarathy HK; Alhashmi K; McMahon AD; Struthers AD; Connell JM; McInnes GT; Ford I; MacDonald TM
    BMC Cardiovasc Disord; 2007 May; 7():14. PubMed ID: 17490489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of low-dose spironolactone in subjects with resistant hypertension.
    Nishizaka MK; Zaman MA; Calhoun DA
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):925-30. PubMed ID: 14573330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
    Ichikawa S; Tajima Y; Sakamaki T; Matsuo H; Kogure M; Hirano Y; Yagi S; Murata K
    Jpn Circ J; 1984 Nov; 48(11):1184-96. PubMed ID: 6502914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)].
    Klump F; Braun B; Klaus D; Lemke R; Zehner J; Zöfel P
    Dtsch Med Wochenschr; 1975 Mar; 100(12):577-84. PubMed ID: 1168122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive responses to spironolactone in normal renin hypertension.
    Ogilvie RI; Piafsky KM; Ruedy J
    Clin Pharmacol Ther; 1978 Nov; 24(5):525-30. PubMed ID: 699476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term spironolactone and the adrenal cortex in essential hypertension.
    Lewis PS; Gorchein A; James VH; May CN; Horth CE
    Clin Endocrinol (Oxf); 1980 Sep; 13(3):273-83. PubMed ID: 7214721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension.
    Simko F; Matúsková J; Lupták I; Pincíková T; Krajcírovicová K; Stvrtina S; Pomsár J; Pelouch V; Paulis L; Pechánová O
    Physiol Res; 2007; 56 Suppl 2():S25-S32. PubMed ID: 17824810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.